We checked out the charts of Emergent Biosolutions on March 4 and concluded that "Despite the positive fundamental story EBS looks like it will retest the December/January lows. A break of the support around $80 will likely precipitate further declines. Sell any remaining longs."
More from Investing
You can't call this market overbought when so much of it isn't participating.
SKLZ shows explosion moves to the upside when it emerges from the oversold area.